InsidersTradesSigma
Track the Cyteir Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, Cyteir Therapeutics, Inc. has published 38 insider filings. The latest transaction was disclosed on 25 March 2024 (Acquisition). Among the most active insiders: Novo Holdings A/S. All data is accessible without an account.
38
Insider Decl.
n/a
Thresholds
€935,141
9 ops.
Buy Volume
€3m
8 ops.
Sell Volume
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 March 2024
Declarations38 total
170,589 shares@ US$2.9559.5% of flowCommon Stock, par value $0.001 per shareSEC:0001373604-24-000010:0
Canonical exit: 18 Jun 2024 (T+90)
113,777 shares@ US$3.0140.5% of flowCommon Stock, par value $0.001 per shareSEC:0001373604-24-000006:0
Canonical exit: 16 Jun 2024 (T+90)
3,239 shares@ US$1.684.9% of flowCommon StockSEC:0001209191-24-004439:0
12,607 shares@ US$1.698.6% of flowCommon StockSEC:0001209191-24-004438:0
14,150 shares@ US$1.69100.0% of flowCommon StockSEC:0001209191-24-003437:0
12,129 shares@ US$1.69100.0% of flowCommon StockSEC:0001209191-24-003348:0
12,828 shares@ US$1.6951.4% of flowCommon StockSEC:0001209191-24-003090:0
14,150 shares@ US$1.6912.2% of flowCommon StockSEC:0001209191-24-002992:0
6,304 shares@ US$1.694.3% of flowCommon StockSEC:0001209191-23-058609:0
1,620 shares@ US$1.682.5% of flowCommon StockSEC:0001209191-23-058610:0
56,737 shares@ US$1.6938.7% of flowCommon StockSEC:0001209191-23-056426:0
52,584 shares@ US$1.6879.8% of flowCommon StockSEC:0001209191-23-056425:0
1,900 shares@ US$2.76160.1% of flowCommon StockSEC:0001209191-23-042977:0
11,000 shares@ US$2.73650.8% of flowCommon StockSEC:0001209191-23-042670:0
200,937 shares@ US$2.634115.2% of flowCommon StockSEC:0001209191-23-040691:0
8,437 shares@ US$1.79050.4% of flowCommon StockSEC:0001209191-23-040129:0
4,834 shares@ US$1.99440.3% of flowCommon StockSEC:0001209191-23-039545:0
10,002 shares@ US$2.030.6% of flowCommon StockSEC:0001209191-23-038567:0
900 shares@ US$2.06450.1% of flowCommon StockSEC:0001209191-23-037208:0
4,100 shares@ US$1.686.0% of flowCommon StockSEC:0001209191-23-007528:0
5,000 shares@ US$1.493.0% of flowCommon StockSEC:0001209191-23-007494:0
5,000 shares@ US$1.496.8% of flowCommon StockSEC:0001209191-23-007536:0
106,345 shares@ US$1.0345.4% of flowCommon StockSEC:0001209191-22-062627:0
21,202 shares@ US$1.3014.4% of flowCommon StockSEC:0001209191-22-060377:0
Canonical exit: 7 Mar 2023 (T+90)
900,000 shares@ US$3.0082.5% of flowCOMMON STOCKSEC:0001209191-22-043049:0
25 of 38 declarations
关于 Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc. 是一家生物制药公司，专注于开发靶向癌症治疗药物。该公司采用创新方法来改善患者预后。
